कंपनी का अवलोकन
Acadia Healthcare Company, Inc. operates within the healthcare sector, specifically functioning in the medical care facilities industry by providing behavioral healthcare services across the United States and Puerto Rico. The organization owns and manages acute inpatient psychiatric facilities alongside specialty treatment centers, which include residential recovery facilities and dedicated eating disorder treatment units. This entity employs approximately 19,000 individuals to deliver these comprehensive services, reflecting a substantial operational footprint in the behavioral health landscape. With a market capitalization of $2.51 billion and annual revenue reaching $3.31 billion, the company demonstrates a significant scale that positions it as a major player in the behavioral healthcare market. These valuation and revenue metrics indicate that Acadia possesses a substantial asset base and revenue generation capacity, allowing it to compete within a specialized industry segment that addresses critical mental health and recovery needs.
वित्तीय स्वास्थ्य
The company reported total revenue of $3.31 billion for the trailing twelve months, yet recorded a net income loss of $1,102,771,968, revealing a cost structure where expenses significantly exceeded total revenues during this period. Despite the negative net income, the entity maintained an EBITDA of $577.21 million, suggesting that core operational cash flows remain positive before financing and tax obligations, though the overall profitability remains compromised. Free cash flow stands at -$370,052,864, indicating that capital expenditures and working capital requirements are currently outpacing operating cash generation, which limits immediate financial flexibility for large-scale acquisitions or dividend distributions. The gross margin is calculated at 41.5%, while the operating margin sits at 5.8% and the profit margin is negative at -33.3%, collectively indicating that while the company retains a portion of revenue to cover direct costs, high operating expenses erode profitability further down the income statement. In terms of leverage, the company holds $133.24 million in cash against total debt of $2.65 billion, resulting in a debt-to-equity ratio of 124.03, which characterizes a highly leveraged balance sheet rather than a conservative one. Short-term liquidity is assessed via a current ratio of 1.55, implying that the company possesses sufficient current assets to cover its current liabilities with a moderate buffer. Return on equity is reported at -41.0%, signaling that shareholder value is currently being diluted, while return on assets stands at 4.2%, showing that the asset base is generating a nominal positive return despite the net loss.
मूल्यांकन आकलन
The valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to the negative earnings, while the forward P/E ratio is 16.23, implying that the market expects earnings to turn positive or improve significantly in the coming fiscal periods. The price-to-book ratio is 1.26, suggesting that the market values the company at a slight premium over its tangible book value, which can occur when intangible assets or future growth potential are factored into the valuation. Alternative valuation measures include a price-to-sales ratio of 0.76 and an EV/EBITDA of 9.05, which provide insight into the company's valuation relative to its revenue and earnings power before interest, taxes, depreciation, and amortization. The stock has experienced significant volatility within the past year, trading between a 52-week low of $11.43 and a 52-week high of $30.17. Without a specific current share price provided in the data, the exact percentage position relative to the trading range cannot be calculated, but the wide range indicates high sensitivity to market sentiment regarding the healthcare sector. The beta value is 0.71, indicating that the stock price exhibits lower volatility relative to the broader market, moving less drastically than the overall index during periods of market stress or rally.
Growth & Income
Revenue growth for the year-over-year period is 6.1%, whereas earnings growth is N/A due to the reported net loss, implying that revenue expansion is currently not translating into proportional profit growth. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means all available cash flow is retained within the business rather than distributed to shareholders. Consequently, the company reinvests its operational cash flows and retained earnings into growth initiatives, facility expansions, or debt management rather than providing income to investors. The overall growth and income profile reflects a high-revenue, low-profit, non-dividend structure typical of capital-intensive healthcare providers facing temporary profitability challenges, with growth currently driven by top-line expansion rather than earnings multiplication or shareholder returns.